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ABSTRACT 
Context: Sex-specific effects of pregnancy calcium carbonate supplementation 
have been reported in 8-12 year old Gambian children, indicating faster growth in 
boys but slower growth in girls born to calcium-supplemented mothers.  
Objective: To determine whether the pregnancy supplement resulted in sex-
specific effects on offspring IGF1 and other growth-related indices in mid-childhood. 
Design: Analysis of archived data obtained in mid-childhood from the children of 
rural Gambian mothers who had been randomised to 1500 mgCa/d (Ca) or placebo 
(P) from 20 weeks pregnancy to delivery (ISRCTN96502494).  
Participants and Methods: Of the 526 children born and followed in infancy, 290 
had early-morning, fasting plasma assayed for IGF1, IGFBP3, leptin, insulin and 
calcium-related indices and had anthropometry performed at age 7.5(SD1.2) years 
(N/group: Males(M)-Ca=64, Females(F)-Ca=77; M-P=76, F-P=73). Sex-specific 
effects of maternal supplementation were considered using regression with sexes 
separated and together to test for sex*supplement interactions. 
Results: Boys had lower IGF1, IGFBP3, leptin and insulin than girls (p≤0.004). 
IGF1 was higher in M-Ca than M-P (+14.2 (SE7.7)%, P=0.05) but lower in F-Ca 
than F-P (-17.8 (SE7.4)%, P=0.01); sex*supplement interaction P=0.001. IGF1 
concentrations (ng/ml, geometric mean [-1SE,+1SE]) were M-Ca=78.1[4.3,4.5], 
M-P=67.8[3.4,3.6]; F-Ca=99.5[4.8,5.1], F-P=118.9[6.4,6.8]). Similar 
sex*supplement interactions were seen for IGFBP3 and IGF1-adjusted-for-IGFBP3 
but group differences were smaller. There were no significant supplement effects on 
the other biochemical indices.  
Conclusions: Calcium carbonate supplementation of pregnant Gambian mothers 
resulted in higher IGF1 in boys and lower IGF1 in girls during mid-childhood, 
consistent with the reported maternal supplement effects on growth of the offspring 
in later childhood.
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Introduction 
We have previously reported unexpected and sex-specific long-term effects of 
calcium carbonate supplementation on the growth and bone development of rural 
Gambian children [1, 2]. Firstly, 12 months of calcium supplementation in 
prepubertal 8-12 year olds (ISRCTN28836000) advanced the timing of the pubertal 
growth spurt in boys, such that peak height velocity was attained earlier than in the 
placebo group [1], with corresponding advancement of the peak velocities of bone 
expansion and mineral accrual [2]. No such effect was seen in girls [1, 2]. These 
findings paralleled those of our trials in British 16-18 year olds in which calcium 
carbonate supplementation for 12 months increased stature and bone growth in 
adolescent boys [3] but not in post-menarcheal girls [4].  
 Secondly, calcium carbonate supplementation of rural Gambian mothers from 
20 weeks pregnancy to term (ISRCTN96502494) resulted in shorter stature and 
smaller bone size and mineral accrual of girls at age 8-12 years and a trend 
towards greater linear growth in boys [5, 6], when no detectable effects had been 
observed at birth, in infancy or at mean age 7.5 years [7-9]. This suggests, as in 
the first study, that the calcium carbonate supplement had resulted in sex-specific 
effects on growth, this time of the offspring, indicated by slower growth in girls and 
accelerated growth in boys by age 8-12 years. 
 A possible explanation for these findings is that calcium carbonate 
supplementation in childhood or in utero altered the activation of the metabolic 
events that trigger the initiation of puberty, advancing skeletal growth and 
development in boys but delaying in girls. This would imply an alteration, in a sex-
specific manner, in the activation of the hypothalamic-pituitary-gonadal (HPA) axis, 
which occurs several years prior to the growth spurt and before the appearance of 
visible pubertal signs [10]. Insulin-like growth factor 1 (IGF1) is a major driver of 
this process [11, 12] and a principal anabolic factor mediating postnatal and 
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pubertal bone growth [13]. Circulating IGF1 in children and adolescents has been 
shown to be raised in response to supplementation with calcium carbonate [14] and 
milk [15, 16] and, in mid-childhood, is predictive of age at menarche in girls [17]. 
This gives rise to the possibility that the findings of the Gambian trials were related 
to effects of the supplement, in childhood and in utero, on circulating IGF1 
concentrations that differed between boys and girls.  
 To investigate this hypothesis, we have conducted an analysis of archived 
biochemical data obtained at mean age 7.5 years from the cohort of Gambian 
children whose mothers had participated in the pregnancy calcium supplementation 
trial. The aim was to test whether the maternal supplement had resulted in sex-
specific effects on the circulating IGF1 and other growth-related indices of their 
offspring in mid-childhood, prior to the age when the differential effects of the 
supplement on their growth were detected.  
 
Subjects and Methods 
Participants and study design 
 Data used in this study were from the children of rural Gambian mothers who 
had participated in a randomised, placebo-controlled trial of calcium 
supplementation in pregnancy between 1995-2000 (ISRCTN96502494), who had 
delivered a healthy singleton baby. These children took part in an investigation of 
the effects of pregnancy calcium supplementation on childhood blood pressure and 
growth between November 2005 and August 2006 at age 5-10 years [9]. Scientific 
approval for the follow-up study was obtained from the Medical Research Council 
(MRC) Laboratories The Gambia Scientific Co-ordinating Committee. Ethical 
approval was granted by The Gambia Government/MRC Laboratories Ethics 
Committee and the London School of Hygiene and Tropical Medicine Ethics 
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Committee. Full written informed consent was obtained from the parents or 
guardians of each child after the purpose of the study had been explained in the 
local language. All the families, investigators and field workers in The Gambia and 
the laboratory staff in Cambridge were blinded to the supplement group allocations. 
 The mothers in the pregnancy trial were residents of the rural province of West 
Kiang, The Gambia, West Africa, latitude 13oN. In this resource-poor region, 
undernutrition is common, calcium intakes are low, childhood growth is poor and 
puberty is delayed [7, 18, 19]. Full details of the pregnancy trial are elsewhere [8] 
but, in brief, the calcium supplement was 1500 mg per day elemental calcium given 
as calcium carbonate (3 tablets of orange-flavoured Calcichew, Nycomed Pharma 
AS distributed in the UK by Shire Pharmaceutical Development Ltd); the matching 
placebo supplement was of cellulose-lactose (Nycomed Pharma AS). The mean 
(SD) calcium intake of mothers, measured in a sub-set of these women at 20 
weeks of pregnancy, was 355 (190) mg/day) [7]. Randomisation was in weekly 
blocks of 4 subjects to minimise confounding by season. The supplements were 
consumed daily in the late afternoon from 20 weeks of pregnancy to term. The 
supplements were well accepted and compliance was high (averaging 97% in both 
groups).  
 The children in the follow-up study had been traced and enrolled following 
village sensitisation meetings. Of the 526 children born and followed into infancy, 
389 children took part; 193 whose mothers had been in the calcium-supplemented 
group, 196 in the placebo group. IGF1 had been determined in blood samples 
where there was sufficient volume (n=290). These were from boys and girls born to 
mothers who had received calcium supplementation (Males (M)-Ca, n=64; Females 
(F)-Ca, n=77) or placebo (M-P, n=76; F-P, n=73). The flow diagram of the 
children, by sex and trial group allocation of their mother, and the characteristics of 
those lost to follow up, is in Figure 1. The children with an IGF1 value were older 
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by 0.5 (0.1) years (P ≤0.001), and were consequently taller and heavier, than the 
other children who participated in the follow-up study but their weights, heights 
and head circumferences during infancy were not significantly different (all P>0.3). 
Randomized 
662 women 
Infancy 
F-Ca 
130 girls 
7.5 years 
F-Ca 
99 girls 
recruited 
Died n=7 
Dropout n=0 
Too distant n=9 
Not located n=0 
Missed/ineligible n=10 
Epilepsy n=0 
Refused n=5 
F-Ca 
77 girls 
with IGF1 
No blood sample n=0 
Insufficient blood n=22 
7.5 years 
M-Ca 
94 boys 
recruited 
Infancy 
M-Ca 
130 boys 
Died n=11 
Dropout n=2 
Too distant n=6 
Not located n=1 
Missed/ineligible n=9 
Epilepsy n=1 
Refused n=6 
M-Ca 
64 boys 
with IGF1 
No blood sample n=2 
Insufficient blood n=28 
Calcium 
330 women 
Dropout n=10 
Did not attend n=10 
Excluded DBD n=39 
Fetal death n=8 
Maternal death n=0 
Multiple birth n=2 
Neonatal death n=1 
7.5 years 
M-P 
99 boys  
recruited  
Infancy 
M-P 
129 boys 
Died n=8 
Dropout n=0 
Too distant n=6 
Not located n=3 
Missed/ineligible n=8 
Epilepsy n=1 
Refused n=4 
M-P 
76 boys  
with IGF1 
No blood sample n=1 
Insufficient blood n=22 
Infancy 
F-P 
137 girls 
7.5 years 
F-P 
97 girls  
recruited 
Died n=9 
Dropout n=1 
Too distant n=11 
Not located n=4 
Missed/ineligible n=10 
Epilepsy n=0 
Refused n=5 
F-P 
73 girls  
with IGF1 
No blood sample n=1 
Insufficient blood n=23 
Placebo 
332 women 
Dropout n=7 
Did not attend n=6 
Excluded DBD n=27 
Fetal death n=14 
Maternal death n=1 
Multiple birth n=9 
Neonatal death n=2 
 
Figure 1. Flow diagram of the children in the study by sex and by trial group allocation of 
their mother. M-Ca = male children of mothers in the calcium supplemented group; F-Ca = 
female children of mothers in the calcium supplemented group; M-P = male children of 
mothers in the placebo group; F-P = female children of mothers in the placebo group; DBD 
= mothers who delivered a term baby before their due date and who therefore had started 
supplementation at a later stage of gestation than specified for the trial. 
 
Blood collection and anthropometry 
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 A venous blood sample (10ml) had been obtained from each child between 
08.00h and 10.00h after an overnight fast. Blood was collected into EDTA for the 
assay of parathyroid hormone (PTH) and into lithium heparin for the other analytes 
reported here. Each sample was placed in an insulated box containing pre-cooled 
freezer packs and transported to the MRC Laboratory in Keneba, West Kiang, for 
immediate processing and storage at -80oC. Samples were subsequently 
transported on dry ice to MRC Human Nutrition Research, Cambridge, UK (now the 
MRC Elsie Widdowson Laboratory) and stored at -80oC prior to analysis between 
July and October 2006.  
 On the day of blood collection, the height, weight, mid-upper arm 
circumference (MUAC) and triceps skinfold thickness (TST) of each child were 
measured [9]. Date of birth and infant growth data were available from the original 
trial [8]. 
 
Biochemical assays 
 The plasma samples were analysed for IGF1, IGF-binding protein 3 (IGFBP3), 
PTH, 1,25-dihydroxyvitamin D (1,25(OH)2D), 25-hydroxyvitamin D (25(OH)D), 
leptin, insulin, calcium, phosphate and albumin. IGF1, IGFBP3 and intact PTH were 
assayed by Immulite 1000 (Diagnostic Products Corporation, Los Angeles, USA), 
1,25(OH)2D by radioimmunassay (IDS), 25(OH)D by chemiluminescent 
immunoassay (Liaison, DiaSorin Inc., Stillwater, USA), the other analytes were 
measured on a Konelab analyser (Thermo Fischer Scientific, Vantaa, Finland) using 
the following Thermo Scientific kits: calcium, arsenazo III method; phosphorus, 
ammonium molybdate method; albumin, bromocresol purple method. PTH values 
<7.0 pg/ml were excluded because, as advised by the manufacturers, these were 
likely due to haemolysis or to interference by excess EDTA when sample volume 
per tube was insufficient, resulting in implausibly low values. Leptin was assayed by 
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Quantikine Solid-Phase ELISA (R&D Systems, Minneapolis, USA). Insulin was 
measured on a 1235 AutoDELFIA automatic immunoassay system using a 2-step 
time–resolved fluorometric assay (Dako Ltd, Turku, Finland) [20] 
 Quality assurance was achieved using control materials supplied by the kit 
manufacturers and commercial materials as follows: minerals and albumin, Roche 
serum control (Roche Diagnostic Corporation, Indianapolis, USA), Lyphochek (Bio-
Rad Laboratories, Herts, UK), NEQAS Clin Chem (Birmingham, UK) and an internal 
plasma drift control; PTH, NEQAS (Edinburgh, UK); for 25(OH)D; and 1,25(OH)2D, 
DEQAS (www.deqas.org). 
 
Statistical analysis 
Data were analysed using DataDesk 6.3.1 (Data Description Inc, Ithaca, NY). 
Summary statistics by group are presented as mean (SE) for normally distributed 
values, and as geometric mean (-1SE, +1SE) for positively skewed data. The latter 
were derived by calculating the mean (SE) in data transformed to natural 
logarithms followed by back transformation. Conventionally, IGF1 divided by 
IGFBP3 is reported as an index of available IGF1. In this data set, IGF1 was more 
closely related to the square root of IGFBP3 (loge[IGF1] = k + 0.54loge[IGFBP3], 
P≤0.0001). For comparison, both the index IGF1:√IGFBP3 and the conventional 
IGF1:IGFBP3 are reported. 
 A square root power transformation provided the best normalisation for the 
IGF1 distribution, as has been reported by others [21], and was used in all models. 
This transformation was also used to model the two indices relating IGF1 to 
IGFBP3. All other data were modelled after transformation to natural logarithms. 
Mean (SE) differences between groups are presented as sympercents 
(difference/mean) derived by multiplying the mean (SE) difference in natural 
logarithms multiplied by 100 [22, 23]. 
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 ANOVA and ANCOVA models were established using the Linear Model software 
within DataDesk, firstly with supplement groups separated to test for differences 
between boys and girls in each group, then with boys and girls separated to test for 
differences between the supplement groups in each sex, and finally with all data 
combined to test for a sex*supplement group interaction. Following this, potential 
covariates were added into full models with stepwise back elimination of non-
significant variables (those with P>0.05).  
 The possibility that any sex and supplement effect might differ across the age 
range of the cohort was tested for in these models by including current age and 
appropriate age interaction terms. Infant length at 52 weeks postpartum was 
included to adjust for the potential influence of size in early life [5], there having 
been no significant effect of the maternal supplement in either boys or girls in 
infancy [8]. Length at 52 weeks was selected to adjust for inter-individual variation 
in infant size because it had been shown previously in growth models of this cohort 
to produce the greatest reductions in the residual variance compared to other 
anthropometric measures between 2 weeks and 52 weeks postpartum [5]. Current 
height, weight and BMI were also considered as potential predictors of the 
biochemical factors. In addition, possible effects of season of birth and maternal 
calcium intake on IGF1 and the response to the supplementation were investigated 
but no significant effects were observed and are not discussed further. 
 Height, weight and BMI standard deviation scores (SD(Z)-scores: HAZ, WAZ, 
BMIAZ) relative to British children of the same age were calculated at the time of 
the original study [9]. These measures are presented as summary statistics but 
were not included as potential covariates in statistical models to avoid artificially 
inflating or diminishing any sex differences because of the known differences in 
maturational delay between Gambian boys and girls when expressed relative to the 
growth trajectories of Western children [18]. 
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Results 
The mean (SE) age of the children was 7.5 (0.1) years (SD 1.2, range 5.4-10.5 
years) and was not significantly different between the four sex-supplement groups 
(P = 0.9). The children had lower attained height, weight and BMI relative to British 
reference children of the same age, as shown by mean SD-scores below zero 
(mean (SE) boys: HAZ = -1.03 (0.07), WAZ = -1.48 (0.08), BMIAZ = -1.04 (0.07); 
girls: HAZ = -0.82 (0.07), WAZ -1.35 (0.08), BMIAZ = -1.27 (0.08)).  
 Table 1 presents the IGF1, IGFBP3 and anthropometric data by sex. Overall, 
boys had significantly lower IGF1, IGFBP3, the two IGF1/IGFBP3 indices, MUAC and 
TST than girls and greater BMI throughout the age range (age*sex interaction: all P 
>0.4). There was no significant difference between boys and girls in height or 
weight. Age was a significant positive predictor of all variables in Table 1 except 
BMI (P = 0.1) but infant size (length at 52 weeks) was only a significant predictor 
of the anthropometric variables. Age adjustment made little difference to the size 
or significance of the sex differences observed in IGF1 and IGFBP3. When adjusted 
for current age and infant size, boys had attained significantly less height, weight, 
MUAC and TST than girls relative to their size in infancy (all P ≤0.001).  
 There were no significant differences in IGF1, IGFBP3 or anthropometric 
variables in the children between the maternal supplement groups with sexes 
combined (all P >0.5). However, a pattern of sex-specific differences between the 
supplement groups emerged when boys and girls were considered separately 
(Table 2 and illustrated for IGF1 in Figure 2).  
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Figure 2. Effect of the maternal calcium supplement on IGF1 in Gambian boys and girls at 
mean age 7.5 years. Data are geometric mean (-1SE, +1SE). Closed circles = children of 
mothers in the calcium supplemented group; open circles = children of mothers in the 
placebo group; ** P = 0.01; * P = 0.05; sex*supplement group interaction P = 0.001. 
 
 In boys, IGF1 was greater in M-Ca than M-P (+14.2 (7.7)%, P = 0.05) 
whereas, in girls, it was lower in F-Ca than F-P (-17.8 (7.4)%, P = 0.01), resulting 
in a significant sex*supplement group interaction term in the joint model (P = 
0.001). Trends consistent with this pattern were also observed for IGFBP3, 
IGF1:√IGFBP3 and IGF1:IGFBP3, with significant interaction terms in joint models 
for IGFBP3 and IGF1:√IGFBP3 (Table 2). Adjustment for age had little or no effect 
on the size and significance of these differences, with the exception of IGF1 in boys 
(M-Ca v M-P = +12.3 (7.2)%, P = 0.07), but the sex*supplement group interaction 
in the joint model remained significant at P = 0.001. There were no significant 
age*supplement group interactions in any of these models, indicating that the sex-
specific differences in IGF1 variables between the supplement groups were 
observed across the age range of the children. 
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 For the anthropometry, M-Ca tended to have greater values for all variables 
than M-P whereas F-Ca tended to have lower values than F-P (Table 2). This 
difference was only statistically significant for BMI in boys (M-Ca v M-P = +2.6 
(1.2)%, p=0.04), equating to a BMIAZ difference of +0.25 (0.1) of a standard 
deviation. The tendency of boys in the calcium group towards greater weight was 
significant after adjustment for age and infant size (M-Ca v M-P: weight = +3.3 
(1.7)%, P = 0.05). The sex*supplement interaction in joint models was not 
significant for any anthropometric variable before adjustment but was for weight (P 
= 0.02) and BMI (P = 0.05) after adjustment for age and infant size. There was no 
indication of a significant interaction of age with any of these effects of supplement 
group, except for MUAC in boys where the difference between M-Ca and M-P was 
greater in older children (age*supplement group P = 0.05).  
 There were highly significant correlations between IGF1, IGFBP3, the IGF/BP3 
indices and all the anthropometric variables in both boys and girls. Adding current 
height and/or weight into models diminished the size and significance of the sex-
specific differences in IGF1 by supplement group, but the pattern of differences was 
unchanged (e.g. IGF1 adjusted for age, height and weight: in boys, M-Ca v M-P = 
+9.4 (6.8)% P = 0.1; in girls, F-Ca v F-P = -12.8 (6.2)%, P = 0.02; 
sex*supplement group interaction: P = 0.007). Adjusting for BMI instead of weight 
gave similar results, with height remaining as a significant co-variable. In boys, but 
not girls, there was a significant height*supplement group interaction for IGF1 and 
its indices (IGF1, P = 0.02; IGF1:√IGFBP3, P = 0.002; IGF1:BP3 P = 0.002), but 
not for IGFBP3 (P = 0.1), indicating that the difference in IGF1 between M-Ca and 
M-P in boys was more pronounced in taller children. Age was not a significant 
predictor, suggesting that the height interaction spanned the age range of the 
boys. There were no significant interactions with weight or BMI for any of these 
variables in either sex. 
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 Table 3 provides the summary statistics for the other growth and calcium-
related analytes by sex-supplement group. There were no significant differences for 
any variable between the maternal supplement groups with sexes separated or 
combined, and there were no significant sex*supplement group interactions. Boys 
had lower leptin and insulin concentrations than girls (M v F in unadjusted models: 
leptin = -72.5 (8.7)%, P <0.001; insulin = -22.3 (6.2)%, P <0.001; these 
differences increased slightly after adjusting for age, height and weight (or BMI)), 
but there were no significant sex differences in the other factors. For both these 
growth factors, the pattern of differences in mean values between the four sex-
supplement groups was similar to that observed for IGF1 and the anthropometry, 
i.e. higher values for boys but lower for girls in the calcium group compared with 
placebo, but these differences were not significant. 
 Age was a significant predictor of plasma insulin (P <0.001, positive), calcium 
(P = 0.02, negative) and albumin (P <0.001, negative), and infant size was a 
predictor of 1,25(OH)2D (P = 0.01, negative) but there were no significant sex or 
supplement group interactions with age or infant size. There were highly significant 
positive inter-relationships between leptin, insulin and the anthropometric variables 
in both boys and girls, which were not age dependent. For insulin, but not leptin, 
there was an interaction between supplement group and BMI such that the 
tendency in boys for insulin to be greater in M-Ca than M-P increased with greater 
BMI (P = 0.04) whereas the tendency in girls for insulin to be lower in F-Ca than F-
P increased with greater BMI (P = 0.06); sex*supplement*BMI interaction in the 
joint model P = 0.006. There were no relationships of the calcium-related variables 
with height, weight or BMI after accounting for age. 
 
Discussion 
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The purpose of this analysis of archived biochemical data from the children of 
Gambian mothers who had participated in a pregnancy calcium supplementation 
trial was to consider whether there was evidence of a sex-specific effect on IGF-1 
and other growth- and calcium-related factors at mean age 7.5 years that presaged 
the differential growth effects observed in the same children later in childhood [5]. 
This proved to be the case for IGF1, with greater values in boys (+14%) and lower 
values in girls (-18%) whose mothers had received the calcium supplement 
compared to their counterparts whose mothers had received placebo. Consistent 
trends similar to the pattern for IGF1 were seen for IGFBP3 and for IGF1 adjusted 
for IGFBP3. No significant sex-specific effects on the other growth- and calcium-
related factors were seen, although the sex-supplement group differences in leptin 
and insulin were in the same direction as for IGF1. Subtle anthropometric 
differences were apparent that mirrored those seen at the later age [5], especially 
the tendency to greater weight and BMI in the boys whose mothers had received 
the calcium supplement, but there was no evidence of the differential effects of the 
maternal supplement on height growth seen later in childhood. 
 The diet in rural Gambia is low in calcium, with intakes averaging 300-400 
mg/d in women and around 200 mg/d in infants and children [7, 19], considerably 
less than international recommendations. The results of this study suggest that the 
increase in calcium intake of the supplemented mothers in the second half of 
pregnancy programmed the growth trajectories of their offspring through a 
mechanism involving alterations in the growth hormone (GH)-IGF1 axis, directly or 
indirectly. This aligns with concepts developed by others (eg reviews by [24-27]) 
whereby the nutritional status of the mother in late pregnancy provides a “forecast” 
of the nutritional environment into which the child will be born and programmes its 
subsequent growth and metabolic pathways [24]. The potential for nutritional 
programming of offspring IGF1 in utero is recognised from trials of milk 
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supplementation in pregnancy and early life [28], from observational studies of 
maternal milk consumption [29], and from extensive studies in animals [30], 
although possible differences in the effects on males and females were not explored 
in many of these studies.  
 The mechanism by which the maternal calcium carbonate supplement may have 
altered the growth trajectories of the offspring in a sex-specific manner is unclear. 
However, sexual dimorphism in fetal growth is well recognised and girls have 
higher circulating IGF1 than boys at birth and throughout childhood [31, 32]. There 
are known sex-differences in the response to environmental factors during fetal life 
such as maternal diet [33], famine [34] and micronutrient supplementation [35], 
and in pregnancies affected by conditions such as asthma and cigarette use [36]. 
Many of these studies report sex-specific effects on insulin-like growth factors, their 
binding proteins and other related growth factors. 
 Several possible mechanisms have been proposed to explain these phenomena, 
including sex-dependent effects on placental size and function [33, 36] and on 
epigenetic modifications through DNA-methylation of growth-related genes [33, 
34]. The former possibility appears a less likely explanation for the long-term 
effects of the maternal calcium carbonate supplement because no discernible 
effects were observed on offspring growth at birth or during the subsequent 12 
months [8]. Because responsiveness to GH largely occurs post-natally [31] and 
there is marked sexual dimorphism in the pattern of GH secretion [24, 31], it is 
possible that the Gambian study indicates sex-specific effects on intrauterine 
programming of GH, on expression of GH receptors at the liver and other tissues, 
or on other factors in the hypothalamic-pituitary-gonadal axis upstream of IGF1 
and IGFBP3 production and bioactivity [24]. 
 Higher plasma IGF1 in mid-childhood is associated with an earlier pubertal 
growth spurt [21], earlier menarche in girls [17] and faster linear growth in later 
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childhood [37]. It is possible, therefore, that the sex-specific effects of the maternal 
supplement on IGF1 at age 7.5y predict faster growth and an earlier puberty in the 
boys and slower growth and later puberty in the girls for those children whose 
mothers received the calcium carbonate supplement. This study is limited by the 
post-hoc nature of the hypothesis under test and by the relatively limited number 
of children from the original trial who provided sufficient blood sample for IGF1 
analysis, although the final numbers and the reasons for loss to follow-up were 
evenly balanced across the four groups. To confirm the apparent sex-specific and 
long-term effects of the maternal supplement on IGF1 and childhood growth, 
longitudinal studies are now in progress involving the entire cohort of children from 
the maternal pregnancy trial as they enter and pass through adolescence. 
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Table 1. IGF1, IGFBP3 and anthropometry of the children by sex 
 
 
  Boys   Girls  P 
 n=140 n=150   
 
 
Age years 7.6 (0.1) 7.5 (0.1) 0.6 
IGF1 ng/ml a,b 72.3 (2.7,2.8) 108.5 (4.0,4.2) ≤0.001 
IGFBP3 µg/ml 2.57 (0.08) 2.90 (0.08) 0.03 
IGF1:√IGFBP3 a,b 46.7 (1.6,1.6) 66.1 (2.2,2.3) ≤0.001  
IGF1: IGFBP3 a,b 29.9 (1.1,1.1) 40.3 (1.6,1.7) ≤0.001 
Height cm 119.2 (0.6) 119.1 (0.7) 0.9 
Weight kg 20.2 (0.3) 19.8 (0.3) 0.3 
BMI kg/m2 14.1 (0.1) 13.9 (0.1) 0.05 
MUAC cm 16.1 (0.1) 16.5 (0.1) 0.005 
TST mm 5.8 (0.1) 7.1 (0.1) ≤0.001 
 
Data are mean (SE), or for positively skewed distributions, geometric mean (-1SE,+1SE) 
calculated with data transformed to logarithms followed by back transformation. BMI, body 
mass index; MUAC, mid-upper arm circumference; TST, triceps skinfold thickness.  
a Positively skewed distribution. b The P values are from models with the dependent variable 
power-transformed to square root, all others from models with data transformed to natural 
logarithms.  
To convert mass units to molar units the following can be used: IGF1 ng/ml = 0.133 nM, 
IGFBP3 µg/ml = 33 nM 
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Table 2. IGF1, IGFBP3 and anthropometry of Gambian boys and girls by maternal supplement group 
 
 
  Boys    Girls  Sex*S/P 
 Calcium Placebo  %∆ (SE) P Calcium Placebo %∆ (SE) P P 
 (M-Ca, n=64) (M-P, n=76)   (F-Ca, n=77) (F-P, n=73) 
 
 
IGF1 ng/mla,b 78.1 (4.3,4.5) 67.8 (3.4,3.6) +14.2 (7.7) 0.05 99.5 (4.8,5.1)c 118.9 (6.4,6.8)c -17.8 (7.4) 0.01 0.001 
IGFBP3 µg/ml 2.72 (0.13) 2.44 (0.09) +11.3 (6.2) 0.07 2.81 (0.11)d 3.00 (0.12)c -7.9 (7.3) 0.3 0.05 
IGF1:√IGFBP3a,b 48.7 (2.6,2.8) 45.0 (1.8,1.9) +8.0 (6.8) 0.2 61.5 (2.7,2.8)e 71.3 (3.6,3.8)c -14.7 (6.8) 0.02 0.008 
IGF1:IGFBP3a,b 30.5 (1.8,2.0) 29.5 (1.2,1.3) +3.4 (7.3) 0.4 38.2 (2.0,2.1)c 42.7 (2.5,2.7)c -11.3 (8.0) 0.2 0.1 
Height cm 119.6 (0.9) 118.8 (0.9) +0.7 (1.0) 0.5 118.5 (0.9) 119.7(1.0) -1.0 (1.1) 0.4 0.3 
Weight kg 20.6 (0.4) 19.8 (0.3) +3.9 (2.6) 0.1 19.5 (0.4)d 20.2 (0.5) -2.8 (2.9) 0.3 0.08 
BMI kg/m2 14.3 (0.1) 13.9 (0.1) +2.6 (1.2) 0.04 13.8 (0.1)e 13.9 (0.1) -1.0 (1.4) 0.5 0.06 
MUAC cm 16.3 (0.2) 15.9 (0.1) +2.1 (1.3) 0.1 16.4 (0.2) 16.7 (0.2)e -1.3 (1.4) 0.4 0.08 
TST mm 5.9 (0.2) 5.7 (0.2) +4.4 (3.8) 0.2 7.0 (0.2)c 7.2 (0.2)c -4.8 (3.5) 0.2 0.08 
 
Data are mean (SE), or, for positively skewed distributions, geometric mean (-1SE,+1SE) calculated with data transformed to logarithms 
followed by back transformation. BMI, body mass index; MUAC, mid-upper arm circumference; TST, triceps skinfold thickness. 
%∆ (SE) = mean (SE) percentage difference, calculated as a sympercent using data transformed to natural logarithms; sex*S/P = 
sex*supplement group interaction term in joint models.  
P values are the significance of differences between the supplement groups with sexes separated and for the sex*supplement group 
interactions in joint models with data transformed to natural logarithms. There were no significant age*supplement group interactions in any 
of these models 
a Positively skewed distribution. b The P values are from models with the dependent variable power-transformed to square root.  
Significance of difference between the sexes within each supplement group: c P≤0.001, d P≤0.05, e P≤0.01 
To convert mass units to molar units the following can be used: IGF1 ng/ml = 0.133 nM, IGFBP3 µg/ml = 33 nM
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Table 3. Growth- and calcium-related factors of Gambian boys and girls by maternal supplement group  
 
 
  Boys    Girls  Sex*S/P 
 Calcium Placebo  %∆ (SE) P Calcium Placebo %∆ (SE) P P 
 (M-Ca, n=64) (M-P, n=76)   (F-Ca, n=77) (F-P, n=73)     
 
 
Leptin ng/mla 0.80 (0.07,0.07) 0.70 (0.05,0.06) +13.6 (11.9) 0.3 1.49 (0.13,0.14) c 1.57 (0.13,0.14)c -5.4 (12.8) 0.7 0.3 
Insulin pmol/la 21.0 (1.2,1.3) 18.1 (1.0,1.1) +14.7 (8.6) 0.2 23.4 (1.5,1.6) 25.2 (1.5,1.6)c -7.4 (8.9) 0.4 0.08 
PTH pg/mla,b 31.1 (2.5,2.7) 34.5 (2.3,2.5) -10.1 (10.7) 0.3 31.6 (2.5,2.7) 36.0 (2.5,2.7) -12.8 (11.0) 0.2 0.9 
1,25(OH)2D pmol/la 231 (10,10) 236 (8.6,9.0) -1.8 (5.7) 0.7 244 (10,10) 251 (11,11) -3.0 (6.0) 0.6 0.9 
25OHD nmol/l 57.2 (1.5) 58.2 (1.4) -1.5 (3.9) 0.7 59.7 (1.7) 57.9 (1.5) +2.3 (3.9) 0.6 0.5 
Calcium mmol/l 2.37 (0.01) 2.38 (0.01) -0.7 (0.8) 0.4 2.38 (0.02) 2.39 (0.02) -0.8 (1.1) 0.5 0.9 
Phosphate mmol/l 1.62 (0.02) 1.60 (0.02) +1.2 (1.7) 0.5 1.56 (0.02) 1.60 (0.02) -3.0 (2.0) 0.1 0.1 
Albumin g/l 38.7 (0.4) 38.7 (0.3) -0.1 (1.3) 0.9 38.9 (0.3) 39.6 (0.4) -1.9 (1.4) 0.2 0.4 
 
Data are mean (SE), or a geometric mean (-1SE,+1SE) calculated with data transformed to logarithms followed by back transformation. 
PTH, parathyroid hormone; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25OHD, 25-hydroxyvitamin D; %∆ (SE) = mean (SE) percentage 
difference, calculated as a sympercent using data transformed to natural logarithms; sex*S/P = sex*supplement group interaction term in 
joint models. P values are the significance of differences between the supplement groups with sexes separated and for the sex*supplement 
group interactions in joint models with data transformed to natural logarithms.  
b n=254 (M-Ca = 59, M-P = 65, F-Ca = 66, F-P = 64). 
c Significance of difference between the sexes within each supplement group: P ≤0.001. There were no other significant differences in any 
measure between calcium and placebo in either sex or between boys and girls in each supplement group or age*supplement group 
interactions in any of these models 
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Highlights 
 
• Pregnancy calcium supplementation (ISRCTN96502494) of Gambian mothers resulted in 
faster childhood growth in boys, slower growth in girls. 
• At mean age 7.5 years, plasma IGF1 of offspring was altered in a sex-specific manner 
before growth effects were evident. 
• Plasma IGF1 was higher in girls than boys. 
• Plasma IGF1 was higher in boys of calcium-supplemented mothers than those of mothers 
who consumed placebo. 
• Plasma IGF1 was lower in girls of calcium-supplemented mothers than those of mothers 
who consumed placebo. 
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